In vitro and in vivo activity of omadacycline against Mycobacterium tuberculosis

The bedaquiline (B), pretomanid (Pa), and linezolid (L) (BPaL) regimen is highly effective for drug-resistant tuberculosis (TB) but is limited by linezolid-associated toxicities, including myelosuppression and peripheral neuropathy. We evaluated omadacycline as a representative tetracycline-class protein synthesis inhibitor (PSI) to assess whether it can contribute functional activity within a BPa backbone. Omadacycline exhibited a minimum inhibitory concentration (MIC) of 2–4 μg/mL against M. t